Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: A study of the US gastric cancer consortium

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3874-3879

  Shah, Manish A ^a,b   Janjigian, Yelena Y ^a,b   Stoller, Ronald ^e   Shibata, Stephen ^f   Kemeny, Margaret ^c   Krishnamurthi, Smitha ^g   Bernard Su, Yungpo ^h   Ocean, Allyson ^b   Capanu, Marinela ^a,b   Mehrotra, Bhoomi ^d   Ritch, Paul ⁱ   Henderson, Charles ^j   Kelsen, David P ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Queen's Cancer Center   (United States)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h Nebraska Cancer Specialists   (United States)

ⁱ MEDICAL COLLEGE OF WISCONSIN   (United States)

^j Piedmont Hospital Research Institute   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CREATININE; DOCETAXEL; FLUOROURACIL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; SIGNAL PEPTIDE; TAXOID;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC GASTRIC ADENOCARCINOMA; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH ADENOCARCINOMA; THROMBOCYTE COUNT; TREATMENT DURATION; ADENOCARCINOMA; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEEDLE BIOPSY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR INVASION; UNITED STATES;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY, NEEDLE; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; UNITED STATES;

EID: 84948456752     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.7465     Document Type: Article

References (15)

1. Jemal A, Bray F, Center MM, et al: Global Cancer Statistics. CA Cancer J Clin 61:69-90, 2011
2. Power DG, Kelsen DP, Shah MA: Advanced gastric cancer: Slow but steady progress. Cancer Treat Rev 36:384-392, 2010
3. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of Her2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
4. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006
5. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: The V-325 Study Group. J Clin Oncol 25:3205-3209, 2007
6. Ajani JA, Moiseyenko VM, Tjulandin S, et al: Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: The V-325 Study Group. J Clin Oncol 25:3210-3216, 2007
7. Ilson DH: Docetaxel, cisplatin, and fluorouracil in gastric cancer: Does the punishment fit the crime? J Clin Oncol 25:3188-3190, 2007
8. Shah MA, Jhawer M, Ilson DH, et al: Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29:868-874, 2011
9. de Gramont A, Bosset JF, Milan C, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French intergroup study. J Clin Oncol 15:808-815, 1997
10. Aapro MS, Walko CM: Aprepitant: Drug-drug interactions in perspective. Ann Oncol 21:2316-2323, 2010
11. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
12. Chow SC, Shao J, Wang H: Sample Size Calculations in Clinical Research. New York, NY, Marcell Dekker, 2003
13. Shah MA, Khanin R, Tang L, et al: Molecular classification of gastric cancer: A new paradigm. Clin Cancer Res 17:2693-2701, 2011
14. Heller G, Venkatraman ES: Resampling procedures to compare two survival distributions in the presence of right-censored data. Biometrics 52: 1204-1213, 1996
15. Siegmund D: Sequential Analysis: Tests and Confidence Intervals - Springer Series in Statistics. New York, NY, Springer, 1985